Merck co-leads Faro AI's $37.3M bet on structured clinical-trial agents
Scott Chetham built Faro after seeing static protocols slow trials; the new round funds agents that can carry study intent into downstream workflows.
By RuntimeWire Staff · Published
Primary source: FinSMEs
Why it matters
Faro is betting that clinical AI will be won below the chatbot layer. Merck's co-lead investment gives Scott Chetham capital and pharma-side validation to turn structured protocols into a control system for regulated agents.
Scott Chetham's Faro AI raised a $37.3 million Series B to extend its structured clinical-development platform into AI agents that can work across study design, execution and regulatory workflows. Merck Global Health Innovation Fund and S32 co-led the financing, according to Faro's August 26th announcement and a report by FinSMEs.…